CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Paclitaxel 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00495170
NCT00495170Phase 2Completed
CompareCT.gov

Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center·interventional·Posted Jul 2, 2007·Updated Feb 6, 2019

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Proton Radiotherapy, and 1 other intervention for Lung Cancer. Completed, enrolled 84 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC. The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2, 2007
Enrollment StartApr 14, 2006
Primary CompletionJun 14, 2017
TodayJul 2, 2026
Enrollment to primary: 11.2 yearsPosted 19 years ago

Interventions

Carboplatindrug

2 area under curve (AUC) by vein Weekly

Proton Radiotherapyradiation

2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).

Paclitaxeldrug

50 mg/m\^2 by vein Weekly